Over 1.8 million children across the globe are affected from HIV, while only half of these have access to the antiretroviral therapy (ART), according to the UNICEF. Evidence assures positive outcomes through early initiation of ART drugs for pediatric HIV infection treatment. Focus of regulatory authorities is increasing on strategic targeting of more decentralized diagnostics along with clinical management for pediatric HIV infection treatment.
Focus is also being placed on the integration of such approaches adolescent, child, and maternal services with communities and at care facilities, which in turn is expected to influence growth of the pediatric HIV infection treatment market. National action plans are being developed across countries worldwide for orphans and other vulnerable children, in a bid to enhance penetration of the pediatric HIV infection treatment.
This paradigm shift toward inclusive programs for aiding vulnerable children with pediatric HIV infection treatment is increasingly becoming a part of social welfare as well as assistance. As majority of the HIV-affected infants are found in the Sub-Saharan Africa, social protection programs are significantly scaling up in the region, which in turn is expected to positively affect growth of the pediatric HIV infection treatment market.
ART continues to remain the mainstay in the pediatric HIV infection treatment, as appropriate antiretroviral therapy as well as treatment of malignancies and infections has been deemed critical for pediatric HIV infection treatment. Pediatric HIV infection treatment market will witness the positive impacts of focus on early intervention as an effective measure to prevent damage to immune system as well as retard dissemination of infection.
During the past few years, the global burden of pediatric HIV infection is becoming a challenge for the healthcare industry. According to the World Health Organization, it is estimated that around 3.2 million people were living with HIV infection at the end of 2013. Majority of children acquire HIV infection from their HIV-infected mothers during pregnancy, breastfeeding or birth. Effective treatments can reduce the risk of mother-to-child HIV transmission. However, in most of the resource-limited countries where the burden of HIV is high, the treatment for pediatric HIV infection is still not widely available.
Pediatric HIV infection causes immunologic deterioration, opportunistic infections, and cancers. Diagnosis of pediatric HIV infection includes viral antibodies and virologic nucleic acid amplification tests. Viral antibodies are given to children above 18 months whereas virologic nucleic acid amplification tests (such as PCR) are performed in children less than 18 months. Combination of antiretroviral drugs is given for the treatment of pediatric HIV infection. The general pathophysiology of pediatric HIV infection is similar to that in adults however, the clinical presentations, the method of infection and treatments often differ.
Worldwide, each year, about 150,000 more children are infected (7 to 10% of all new infections) with HIV infection, and about 110,000 children die. Some of the risk factors related to the vertical transmission of HIV infection in children include high plasma viral RNA concentrations, seroconversion during pregnancy or breastfeeding, advanced maternal disease, and low maternal peripheral CD4+ T-cell counts.
The most common signs of pediatric HIV infection not receiving ART include generalized lymphadenopathy, splenomegaly, oral candidiasis, hepatomegaly, CNS disease, failure to thrive, recurrent bacteremia, lymphoid interstitial pneumonitis, hepatitis, nephropathy, and others.
The market for pediatric HIV infection treatment is primarily driven by increasing prevalence of HIV infection in children. Active involvement of national and international government bodies to promote the research on HIV infection treatment drugs is responsible to drive the growth of the market during the forecast period. Moreover, increasing private-public partnerships for the research and development activities and increasing healthcare expenditure are also some of the factors driving the growth of the pediatric HIV infection treatment market.
However, unavailability of treatment options in the underdeveloped countries can be the factor which can hamper the growth of global pediatric HIV infection treatment market. Moreover, the limited number of treatment options with a very high cost of branded drugs in various regions have impeded the growth of the global pediatric HIV infection treatment market.
Pediatric HIV Infection Treatment Market: Key Players
Examples of some of the key players present in the global pediatric HIV infection treatment market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Apotex Inc., and others.
Know More Details About the Report
The report covers exhaustive analysis on:
- Pediatric HIV Infection Treatment Market Segments
- Pediatric HIV Infection Treatment Market Dynamics
- Historical Actual Market Size, 2012 - 2016
- Pediatric HIV Infection Treatment Market Size & Forecast 2016 to 2024
- Pediatric HIV Infection Treatment Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Pediatric HIV Infection Treatment Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Avail customized purchase options for your needs
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size Recent industry trends
- Key Competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
The global market for pediatric HIV infection treatment is segmented on basis of HIV infection types, treatment, distribution channel and geography:
- Segmentation by Type
- Not symptomatic
- Mildly symptomatic
- Moderately symptomatic
- Severely symptomatic
- Segmentation by Treatment
- Antiretroviral (ARV) drugs
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Protease Inhibitor (PI)
- Integrase Strand Transfer Inhibitor (INSTI)
- Supportive care
- Antiretroviral (ARV) drugs
- Segmentation by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of geography, global pediatric HIV infection treatment market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and Middle East & Africa. North America is expected to witness faster revenue growth in comparison with markets in other regions owing to higher infection rate amongst children and a large number of pediatric population suffering from HIV infection.
Asia Pacific is also one of the fast growing regions in the global pediatric HIV infection treatment market due to high involvement of government-non-government bodies in promoting HIV infection treatment campaigns. Moreover, the Middle East and Africa and Latin America are expected to show less growth in the global pediatric HIV infection treatment market due to delayed introduction of treatment therapies in the regions.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
The Rise of Intelligent Packaging
Personalized, Connected and Sustainable
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.